A Phase 3 interventional study of Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy in Asthma, sponsored by AstraZeneca. Completed at 53 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
The purpose of the study is to compare the efficacy of a flexible dose of Symbicort with conventional stepwise treatment according to asthma treatment guidelines in patients with persistent asthma
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 83 across 2,752 interventional studies indexed under Asthma.
Browse Asthma studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Additional inclusion and exclusion criteria will be evaluated by the investigator.
Also known as: Symbicort
Time to first severe asthma exacerbation
Number of asthma exacerbations
Mean use of as-needed medication
Prescribed asthma medication
Asthma Control Questionnaire
Asthma related costs (direct asthma medication, direct non-medication costs and indirect costs)
Safety: Serious Adverse Events and discontinuations due to adverse events
All variables assessed over the 6 months treatment period
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca